Mattern Capital Management LLC Buys 1,127 Shares of Zoetis Inc. $ZTS

Mattern Capital Management LLC raised its stake in shares of Zoetis Inc. (NYSE:ZTS) by 2.2% during the 2nd quarter, Holdings Channel.com reports. The fund owned 53,497 shares of the company’s stock after purchasing an additional 1,127 shares during the quarter. Mattern Capital Management LLC’s holdings in Zoetis were worth $8,343,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Ashton Thomas Securities LLC lifted its stake in Zoetis by 11.3% during the 2nd quarter. Ashton Thomas Securities LLC now owns 1,483 shares of the company’s stock valued at $231,000 after acquiring an additional 150 shares during the period. River Street Advisors LLC lifted its stake in shares of Zoetis by 33.3% in the 2nd quarter. River Street Advisors LLC now owns 3,614 shares of the company’s stock worth $564,000 after purchasing an additional 903 shares during the period. Hilltop National Bank bought a new position in shares of Zoetis in the 2nd quarter worth approximately $764,000. OLD Second National Bank of Aurora lifted its stake in shares of Zoetis by 17.1% in the 2nd quarter. OLD Second National Bank of Aurora now owns 13,693 shares of the company’s stock worth $2,135,000 after purchasing an additional 2,000 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Zoetis by 9.1% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 74,738 shares of the company’s stock worth $11,655,000 after purchasing an additional 6,230 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of NYSE ZTS opened at $146.46 on Friday. The firm has a fifty day moving average price of $149.89 and a 200-day moving average price of $155.26. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The stock has a market cap of $64.91 billion, a PE ratio of 25.21, a price-to-earnings-growth ratio of 2.36 and a beta of 0.90. Zoetis Inc. has a 1 year low of $139.34 and a 1 year high of $196.55.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. The firm had revenue of $2.46 billion during the quarter, compared to analysts’ expectations of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same period in the prior year, the company posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Leerink Partnrs cut shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Leerink Partners cut shares of Zoetis from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Piper Sandler increased their price objective on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Argus reiterated a “buy” rating and issued a $190.00 price objective on shares of Zoetis in a research note on Tuesday, September 9th. Finally, Stifel Nicolaus cut shares of Zoetis from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Five research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $200.88.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.